Pediatric Multiple Sclerosis

Ji Y Lee1, Tanuja Chitnis1

  • 1Department of Pediatric Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Seminars in Neurology
|April 27, 2016
PubMed

Insights

Pediatric multiple sclerosis (MS) presents unique challenges due to developmental neuroimmune processes. Understanding gene-environment interactions is crucial for diagnosing and treating this chronic neurologic disease in children.

Area of Science:

  • Neuroimmunology
  • Pediatric Neurology

Background:

  • Pediatric multiple sclerosis (MS) is a chronic inflammatory neurologic disease.
  • It shares similarities with adult MS but has distinct features due to developmental neuroimmune processes.

Purpose of the Study:

  • To describe clinical features, diagnosis, and treatment of pediatric MS.
  • To highlight new developments in understanding pediatric MS pathogenesis.
  • To emphasize the need for research into gene-environment interactions in pediatric MS.

Main Methods:

  • Review of clinical features in pediatric MS.
  • Discussion of diagnostic and treatment strategies.
  • Exploration of emerging research in pediatric MS pathogenesis.

Main Results:

  • Pediatric MS exhibits unique clinical features influenced by developmental factors.
  • Early gene-environment interactions are critical for MS etiology in children.
  • Biomarkers are needed for onset definition, treatment response, and disease monitoring.

Conclusions:

  • Further understanding of pediatric MS pathogenesis is essential.
  • Research into gene-environment interactions will advance diagnosis and treatment.
  • Development of robust biomarkers is vital for long-term management of pediatric MS.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
315
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
441
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
368
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
669